| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000014657 |
| Receipt No. | R000017006 |
| Scientific Title | Application of FDG-PET/CT for fever of unknown origin: a comparative study to Gallium SPECT |
| Date of disclosure of the study information | 2014/07/29 |
| Last modified on | 2019/03/18 (Ver. 11) |
| Basic information | ||
| Public title | Application of FDG-PET/CT for fever of unknown origin: a comparative study to Gallium SPECT | |
| Acronym | JPET-FUO | |
| Scientific Title | Application of FDG-PET/CT for fever of unknown origin: a comparative study to Gallium SPECT | |
| Scientific Title:Acronym | JPET-FUO | |
| Region |
|
|
| Condition | |||||
| Condition | Fever of unknown origin (FUO) | ||||
| Classification by specialty |
|
||||
| Classification by malignancy | Others | ||||
| Genomic information | NO | ||||
| Objectives | |
| Narrative objectives1 | To demonstrate the usefulness of FDG-PET/CT for the diagnosis of fever of unknown origin (FUO), we will compare the sensitivity of FDG-PET/CT and that of gallium SPECT for the detection of fever origin. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Explanatory |
| Developmental phase | Phase III |
| Assessment | |
| Primary outcomes | The primary endpoint of the study will be the difference in the sensitivity of FDG-PET/CT and that of gallium SPECT for the detection of fever origin. |
| Key secondary outcomes | Secondary endpoints
<Based on the Central Image Interpretation Committee's report> - Positive lesions on FDG-PET/CT images - Sensitivity, specificity, positive predictive value, accuracy, and contribution ratio of FDG-PET/CT - Positive lesions on gallium SPECT images - Sensitivity, specificity, positive predictive value, accuracy, and contribution ratio of gallium SPECT <Based on the case report file completed by the physician in charge> - Clinical impact of FDG-PET/CT on the final diagnosis of FUO. - Clinical impact of gallium SPECT on the final diagnosis of FUO <Additional evaluation> - Consistency of positive lesions identified by the hospital radiologist and that identified by the Central Image Interpretation Committee. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |||
| No. of arms | 1 | ||
| Purpose of intervention | Diagnosis | ||
| Type of intervention |
|
||
| Interventions/Control_1 | FDG-PET/CT examination and Gallium SPECT examination. | ||
| Interventions/Control_2 | |||
| Interventions/Control_3 | |||
| Interventions/Control_4 | |||
| Interventions/Control_5 | |||
| Interventions/Control_6 | |||
| Interventions/Control_7 | |||
| Interventions/Control_8 | |||
| Interventions/Control_9 | |||
| Interventions/Control_10 | |||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Inclusion criteria
1. Patients who were 20 years old or older when they signed the informed consent form. 2. Patients with a fever of 38degree Cercius or higher (axillary temperature) on two occasions per week or more during the 14 days prior to the provision of consent to participate to this study. 3. Patients in whom a cerebrospinal fluid (CSF) examination performed within 3 weeks after fever onset produced normal results or patients who did not exhibit neck stiffness or a disturbance of consciousness. 4. Patients whose fever origin remained undiagnosed even after the completion of blood tests, a thoracic-abdominal CT examination, and other tests listed below within 3 weeks before the provision of consent to participate in this study. Patients, including those with sepsis, whose focus of infection was unknown were regarded as having FUO. -complete blood cell count, blood sedimentation, blood chemistry (T-Bil, AST, ALT, LDH, ALP, gammaGTP, BUN, Cr, Na, K, Cl, Ca, BS), serological tests (CRP, TP, Alb, ferritin, RF, antinuclear antibody), thyroid tests (F-T3, F-T4, TSH), viral antibody (HIV-Ab, CMV-IgM, EB VCA IgM), urine test, blood culture, and echocardiography. 5. Patients who provided written informed consent. |
|||
| Key exclusion criteria | Exclusion criteria
1. Patients who had undergone surgery within 1 month. 2. Pregnant or lactating patients. 3. Patients with uncontrolled diabetes mellitus. 4. Patients with neutrophil counts lower than 500/micro Litter 5. Patients who had already undergone an FDG-PET/CT or gallium SPECT examination within 3 weeks. 6. Patients who were suspected of not being able to provide full voluntary agreement to participate in this research study because of mental and/or legal problems. |
|||
| Target sample size | 180 | |||
| Research contact person | |||||||
| Last name of lead principal investigator |
|
||||||
| Organization | National Center for Global Health and Medicine | ||||||
| Division name | Division of Nuclear Medicine, Department of Radiology. | ||||||
| Zip code | |||||||
| Address | 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, JAPAN | ||||||
| TEL | 03-5273-6881 | ||||||
| fumeinetsu@clock.ocn.ne.jp | |||||||
| Public contact | |||||||
| 1st name of contact person |
|
||||||
| Organization | National Center for Global Health and Medicine | ||||||
| Division name | Division of Nuclear Medicine, Department of Radiology. | ||||||
| Zip code | |||||||
| Address | 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, JAPAN | ||||||
| TEL | 03-5273-6881 | ||||||
| Homepage URL | |||||||
| fumeinetsu@clock.ocn.ne.jp | |||||||
| Sponsor | |
| Institute | National Center for Global Health and Medicine |
| Institute | |
| Department | |
| Funding Source | |
| Organization | National Center for Global Health and Medicine |
| Organization | |
| Division | |
| Category of Funding Organization | Government offices of other countries |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | |
| Address | |
| Tel | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 国立国際医療研究センター病院(東京都)、東北大学病院(宮城県)、公立大学法人横浜市立大学附属病院(神奈川県)、東京医科歯科大学医学部付属病院(東京都)、山形大学医学部付属病院(山形県)、大阪市立大学医学部付属病院(大阪府)、香川大学医学部付属病院(香川県)、大阪大学医学部付属病院(大阪府)、慶応義塾大学病院(東京都)、宮崎大学医学部付属病院(宮崎県)、公立松任石川中央病院(石川県)、社会福祉法人恩師財団大阪府済生会中津病院(大阪府)、東京都健康長寿医療センター(東京都)、独協医科大学病院(栃木県)、京都大学医学部附属病院(京都府)、長崎大学病院(長崎県)、九州大学病院(福岡県) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000017006 |